As shown in Fig. 3B, treatment of pancreatic cancer cells with pristimerin caused a significant reduction decrease in the protein levels of cyclins D1 and E in a concentration-dependent manner in all three pancreatic cancer cell lines tested. This evidence concerns the gene CCND1 and pancreatic neoplasm.